Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 10Salivary Gland Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1Glioma 1

Interventions

pembrolizumab 4olaparib 3atezolizumab 3Cetuximab 3Trastuzumab 2Docetaxel 2zimberelimab 1tocilizumab 1spartalizumab 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1ipatasertib 1inavolisib 1fludarabine phosphate 1fludarabine 1entrectinib 1encorafenib 1dapagliflozin 1cemiplimab 1binimetinib 1anlotinib 1amivantamab 1alectinib 1adagrasib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Ado-Trastuzumab Emtansine × 90 days × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡